Fingerprint
Dive into the research topics of 'Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically